The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis

• मुख्य लेखकों: Emanuela Talamonti (लेखक), Jelena Davegardh (लेखक), Anastasia Kalinovich (लेखक), Sten M.M. van Beek (लेखक), Nodi Dehvari (लेखक), Carina Halleskog (लेखक), Hamza M. Bokhari (लेखक), Dana S. Hutchinson (लेखक), Seungmin Ham (लेखक), Laura J. Humphrys (लेखक), Nicola C. Dijon (लेखक), Aikaterini Motso (लेखक), Anna Sandstrom (लेखक), Evelyn Zacharewicz (लेखक), Ilga Mutule (लेखक), Edgars Suna (लेखक), Jana Spura (लेखक), Karolina Ditrychova (लेखक), Leigh A. Stoddart (लेखक), Nicholas D. Holliday (लेखक), Shane C. Wright (लेखक), Volker M. Lauschke (लेखक), Soren Nielsen (लेखक), Camilla Scheele (लेखक), Elizabeth Cheesman (लेखक), Joris Hoeks (लेखक), Peter Molenaar (लेखक), Roger J. Summers (लेखक), Benjamin Pelcman (लेखक), Gopala K. Yakala (लेखक), Tore Bengtsson (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Elsevier, 2024-07-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Objective: Simultaneous activation of β2- and β3-adrenoceptors (ARs) improves whole-body metabolism via beneficial effects in skeletal muscle and brown adipose tissue (BAT). Nevertheless, high-efficacy agonists simultaneously targeting these receptors whilst limiting activation of β1-ARs - and thus...